Vnitr Lek 2007, 53(7-8):807-811

Endocrinology and nuclear medicine aspects of the treatment of thyroid tumours

P. Vlček
Klinika nukleární medicíny a endokrinologie 2. lékařské fakulty UK a FN Motol, Praha, přednosta doc. MUDr. Petr Vlček, CSc.

Thyroid tumours belong among the most frequent malignant tumours in endocrinology. The rate of incidence of new carcinomas has increased dramatically in recent years; the rate of thyroid tumour incidence, in particular of its less advanced papillary forms, sextupled in the Czech Republic in the previous decade. The article brings an overview of the factors involved in the development of thyroid tumours, and the classification and clinical assessment of their different types. Recombinant human TSH has started to be used in the Czech Republic as part of preparation of patients for radioiodine treatment. Also discussed is the relevance of tumour markers for the prognosis of the disease in the context of life-long monitoring of patients with thyroid carcinoma.

Keywords: thyroid carcinoma; radioiodine; recombinant TSH; microtumour; prognosis

Received: March 23, 2007; Published: July 1, 2007  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Vlček P. Endocrinology and nuclear medicine aspects of the treatment of thyroid tumours. Vnitr Lek. 2007;53(7-8):807-811.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Miller B, Kolonel LN, Bernstein L et al. Radical/ethnic patterns of cancer in the United States 1988-1992. Cancer Institute NIH Pub 1996, No. 96-4104.
    2. Davies L, Welch HG. Increasing incidence of thyroid cancer in the United Stattes, 1972-2002. JAMA 2006; 295: 2164-2167. Go to original source... Go to PubMed...
    3. Pacini F, Vorontsova T, Demidchik EP et al. Post-Chernobyl thyroid carcinoma in Belarus chlidren and adolescents: comparison with naturally occurring thyroid carcinoma in Italy and France. J Clin Endocrinol Metab 1997; 82: 3563-3569. Go to original source...
    4. Němec J et al. Pokroky v diagnostice a léčbě nemocí štítné žlázy. 1. ed. Praha: Avicenum 1975.
    5. Sarlis NJ. Thyroid Cancer in Childhood. In: Mazzaferri EL, Hamer C, Mallick UK. Practical Management of Thyroid Cancer. London: Springer-Verlag 2006: 303-320. Go to original source...
    6. Block MA, Jackson CE, Greenawald KA et al. Clinical characteristics distinguishing hereditary from sporadic medullary thyroid carcinoma. Arch Surg 1980; 115: 142-148. Go to original source... Go to PubMed...
    7. Jindřichová Š, Vlček P, Bendlová B. Genetické příčiny vzniku karcinomů štítné žlázy. Čas Lék Čes 2004; 143: 664-668.
    8. Dvořák J, Neumann J. Chirurgická léčba karcinomu štítné žlázy. Čas Lék Čes 1995; 134: 374-377.
    9. Vlček P, Neumann J. Karcinom štítné žlázy, pooperační sledování nemocných. Praha: Maxdorf 2002.
    10. Waxmann A, Ramanna L, Chapman N et al. The significance of I-131 scan dose in patients with thyroid cancer: determination of ablation. J Nucl Med 1981; 25: 861-865.
    11. Schlumberger M, Mancusi F, Baudin E et al. 131I therapy for elevated thyroglobulin levels. Thyroid 1997; 7: 273-276. Go to original source... Go to PubMed...
    12. Schlumberger M, Pacini F. Thyroid tumors. Paris: Nukleon 1999.
    13. Mazzaferri E. Long-term outcome of patients with differentiated thyroid carcinoma: effect of therapy. Endocr Pract 2000; 6: 469-476. Go to original source... Go to PubMed...
    14. Němec J, Bílek P, Zamrazil V et al. The prognostic value of plasma thyroglobulin at the time of hypothyroidism and the differentiated thyroid cancer. Nuklear Medizin 1995; 34: 154.

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.